Compare like-for-like revenue
The reported-period revenue series records USD 8.69m for the period ended June 30, 2026. That is 37.4% above the same reporting basis a year earlier.
—
—
—
Advanced Flower Capital (formerly AFC Gamma)
—
—
Live Price
CIN RESEARCH · DATED EVIDENCE
Dated financial evidenceAdvanced Flower Capital (formerly AFC Gamma): revenue expanded; follow the cash evidence.
The reported-period revenue series records USD 8.69m for the period ended June 30, 2026. That is 37.4% above the same reporting basis a year earlier. Cash and operating cash flow are available on a matching dated basis.
Latest financial observation 2026-06-30Last reported price 2026-11-06Research checked 2026-11-07 13:30 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Put cash beside operating cash flow
Period-end cash was USD 106.51m at 2026-06-30. The matching reported-period operating cash inflow was USD 636,282. Later financing and cash movements are not established by this snapshot.
Follow the primary disclosures
The available record includes 2 primary disclosures. The latest is 2026-06-30. This is the available feed record, not a claim of complete filing coverage.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| Revenue | USD 8.69mUnit: USD | Quarterly series | Dated financial series |
| Cost of revenue | USD 1.64mUnit: USD | Quarterly series | Dated financial series |
| Gross profit | USD 7.05mUnit: USD | Quarterly series | Dated financial series |
| Operating income | USD 7.74mUnit: USD | Quarterly series | Dated financial series |
| EBITDA | USD 7.95mUnit: USD | Quarterly series | Dated financial series |
| Cash balance | USD 106.51mUnit: USD | Balance at period end | Dated financial series |
| Total assets | USD 399.72mUnit: USD | Balance at period end | Dated financial series |
| Total liabilities | USD 212.45mUnit: USD | Balance at period end | Dated financial series |
| Shareholders’ equity | USD 187.27mUnit: USD | Balance at period end | Dated financial series |
| Operating cash flow | USD 636,282Unit: USD | Quarterly series | Dated financial series |
| Free cash flow | USD 636,280Unit: USD | Quarterly series | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What changed against the prior year
Only the same measure, unit, reporting frequency and prior-year period end are compared. A reported change is not an investment rating.
Increased +37.4%
- 2025-06-30
- USD 6,325,181
- 2026-06-30
- USD 8,691,805
Decreased -90.7%
- 2025-06-30
- USD 17,709,740
- 2026-06-30
- USD 1,640,827
Increased
- 2025-06-30
- USD -11,384,559
- 2026-06-30
- USD 7,050,978
Increased
- 2025-06-30
- USD -13,302,695
- 2026-06-30
- USD 7,738,280
Increased
- 2025-06-30
- USD -13,085,312
- 2026-06-30
- USD 7,946,414
Increased +3023.4%
- 2025-06-30
- USD 3,410,065
- 2026-06-30
- USD 106,508,623
Increased +37.6%
- 2025-06-30
- USD 290,589,955
- 2026-06-30
- USD 399,718,181
Increased +100.7%
- 2025-06-30
- USD 105,858,881
- 2026-06-30
- USD 212,448,681
Increased +1.4%
- 2025-06-30
- USD 184,731,074
- 2026-06-30
- USD 187,269,500
Decreased -63.8%
- 2025-06-30
- USD 1,759,991
- 2026-06-30
- USD 636,282
Decreased -63.8%
- 2025-06-30
- USD 1,759,991
- 2026-06-30
- USD 636,280
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Read the latest linked company disclosures and any reporting after the financial period.
- Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- Interim frequency is provider-classified. Generic form labels are not treated as proof of an SEC filing or a three-month reporting duration.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Primary company disclosures
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · USD
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH